For ultrasound-guided prostate biopsy, a transperineal approach is emerging as a superior alternative to the transrectal approach because the former is associated with a lower risk of infection. This ...
A consultant urological surgeon has explained why you need to prepare before a cancer check ...
URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.
Using both PSMA PET and mpMRI before cognitive targeted biopsy improved specificity for clinically significant prostate cancer from 54.6% to 86.3%. For men undergoing evaluation for suspected prostate ...
Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...
In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...
The European Society for Medical Oncology has updated its clinical practice guidelines for the management of localised prostate cancer and biochemical recurrence, refining diagnostic pathways and ...
The MarketWatch News Department was not involved in the creation of this content. GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", ...
Introduction: The BIOPSTAGE trial investigates the added diagnostic value of combining prostate-specific membrane antigen positron emission tomography (PSMA PET) with multiparametric MRI (mpMRI) for ...
Digital Health News: Daniel Spratt, chair of radiation oncology at Case Comprehensive Cancer Center, commented on a new AI-enabled prostate cancer risk assessment tool has been developed to analyze ...
Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results